Strides Pharma Science Ltd. has announced that its step down subsidiary, Strides Pharma Global Pte, Singapore (SPG) has entered into a Joint Venture (JV) with Sun Moral International (HK) Ltd., a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan), one of China’s leading pharmaceutical companies. The JV, Sihuan Strides HK Ltd., will be 49% owned by SPG, while the Sun Moral International (HK) will own the balance 51%.
The JV fast tracks Strides’ entry into China, the second-largest pharmaceutical market in the world offering a $137-bn market opportunity. Sihuan is one of the leading pharmaceutical companies in China’s prescription drug market with a market share of 8.3% in the cardio-cerebral vascular market and strong positioning in other therapeutic areas.
The recent regulatory developments in China have enabled fast track approvals of differentiated high-quality generics approved in key regulated markets. “Strides’ specialised basket of 140+ products qualifies for the programme, and this JV will be able to leverage it in China,” Strides said in a official statement.
Strides will immediately license four high potential products to the JV, which will add significant value to Sihuan’s existing portfolio. In return, Strides will receive a licensing fee for each product in-licensed to the JV. Strides will supply these products to the JV from its manufacturing facilities at India and Singapore. The JV will explore setting up local manufacturing in China in due course.
“The cooperation between Sihuan Pharmaceutical and Strides is a powerful collaboration. Sihuan will give full scope to the JV in sales and marketing strategies and continue to expand the market rapidly through our marketing channels,” Dr. Che Fengsheng, Chairman and Executive Director, Sihuan, remarked.
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pharmaceutical and Health Industry Special Study - The Arrival of New Opportunities
-
Accelerate Technological Breakthroughs in Product Innovation and Promote the Industrialization and Application of Innovative Drugs
-
The Rare Disease Market Continues to Heat Up. How Will The Global Top 10 Pharmaceutical Companies by Revenue in 2021 be Deployed?
-
Top 10 Global CDMO Rankings in 2022
-
Bayer, Merck Announced to Close Two Factories
-
5 Chinese Pharmaceutical Companies Authorized to Produce Key Ingredients of Pfizer's COVID-19 Oral Drug
-
The 88th APIChina meet you in Qingdao!
-
How Long is Amoxicillin Good for in the Fridge
-
VPi's Weakness Slows Down, And Inventory Positions Are Basically Formed
-
Analysis of The Domestic Pharmaceutical Raw Material Market In The Third Week of 2022
Recommend Reading
-
Top 10 Development Trends in the Chemical Industry in the Context of Carbon Neutrality!
-
Covestro expands open innovation in China
-
LANXESS looks at China Daily Chemicals: Towards higher-end and safer
-
Raw Materials Soared to 210,000 Yuan / ton! The Price of Chemical Raw Materials Has Been Raised Collectively!
-
India wants to spend 23 billion to reduce chemical imports to China
-
Jiangsu 18 square kilometers chemical industry core area closed management
-
Tea Baidao Chengdu Built Biodegradable Environmental Protection Packaging Materials Project
-
A Coal Washing Plant Occupied River Channel and Dumped Coal Slime
-
The groundbreaking ceremony for Clariant China's third catalyst plant in Jiaxing
-
ASHLAN SELLS COMPOSITE COMPOSITES AND BUTYLENE GLYCOL FACTORY IN GERMANY